House Energy and Commerce Health Subcommittee Holds Hearing on the Prescription Drug Supply Chain

Today, the House Energy and Commerce Health Subcommittee held a hearing on lowering health care costs throughout the prescription drug supply chain. The hearing featured nine witnesses representing all major aspects of the supply chain, including manufacturers and biotechnology companies, pharmacy benefit managers (PBMs), health care group purchasing organizations (GPOs), pharmaceutical wholesalers, employer groups, community pharmacists and academia. While Republicans, Democrats, and witnesses discussed varying opinions on the role of each actor in the supply chain, there was striking agreement between committee leaders of both parties to pursue additional oversight into the details of the Trump administration’s Most-Favored-Nation non-public drug pricing arrangements with 16 manufacturers. Committee members also discussed the recently unveiled TrumpRx drug pricing platform, which was designed to provide MFN prices to cash-paying patients.

Full Brief